NEW YORK (GenomeWeb) – Cellecta has recently received a six-month Phase I SBIR grant from the National Institutes of Health to develop a validated set of reagents for targeted CRISPR/Cas9-based genome editing.

CRISPR/Cas9 involves the use of a specific enzyme to cause double-strand DNA breaks that induce gene silencing. The process can be targeted to specific areas of the genome using so-called guide RNAs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.